Luis Ruilope

Summary

Affiliation: Hypertension Unit
Country: Spain

Publications

  1. ncbi request reprint Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08903 0019, USA
    Am J Hypertens 15:193-8. 2002
  2. ncbi request reprint Chronic kidney disease as a situation of high added risk in hypertensive patients
    Julian Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, 28041 Madrid, Spain
    J Am Soc Nephrol 17:S136-40. 2006
  3. ncbi request reprint Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 25:1473-9. 2007
  4. ncbi request reprint [Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]
    Cristina Sierra
    Unidad de Hipertension, Servicio de Medicina Interna, Hospital Clinic, Barcelona, Espana
    Med Clin (Barc) 129:1-5. 2007
  5. ncbi request reprint Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre Madrid, Spain
    J Hypertens 25:1711-8. 2007
  6. doi request reprint The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041, Madrid, Spain
    Adv Ther 30:1086-99. 2013
  7. doi request reprint Can the effectiveness of hypertension management be improved?
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Autonoma University, 28041, Madrid, Spain
    Expert Rev Cardiovasc Ther 11:689-95. 2013
  8. doi request reprint Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition
    Julian Segura
    Hospital 12 de Octubre, Department of Nephrology, Hypertension Unit, Av Cordoba s n, 28041 Madrid, Spain
    Expert Opin Investig Drugs 22:915-25. 2013
  9. doi request reprint The Clinical Significance of Blood Pressure Lowering Treatment: First-Line Drug Choice is Important : The Pro Position
    Luis M Ruilope
    Hypertension Unit, Unidad de Hipertension, Hospital 12 de Octubre, Avda Cordoba s n, 28041, Madrid, Spain
    High Blood Press Cardiovasc Prev 15:113-5. 2008
  10. doi request reprint Current status of renal denervation in resistant hypertension
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, and Department of Preventive Medicine and Public Health, Universidad Autonoma, Madrid, Spain
    J Am Soc Hypertens 6:414-6. 2012

Collaborators

Detail Information

Publications98

  1. ncbi request reprint Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial
    John B Kostis
    University of Medicine and Dentistry of New Jersey Robert Wood Johnson Medical School, New Brunswick 08903 0019, USA
    Am J Hypertens 15:193-8. 2002
    ..Additional analyses will be conducted in men and women, in diabetic patients, in different risk classes and according to prior evidence of vascular disease...
  2. ncbi request reprint Chronic kidney disease as a situation of high added risk in hypertensive patients
    Julian Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, 28041 Madrid, Spain
    J Am Soc Nephrol 17:S136-40. 2006
    ..This paper briefly reviews the most recent evidences about pharmacologic therapies in high-risk patients, focusing on benefits related to improvement of cardiovascular risk factors in hypertensive patients with chronic kidney disease...
  3. ncbi request reprint Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 25:1473-9. 2007
    ..Reduced renal function is predictive of poor cardiovascular outcomes but the predictive value of different measures of renal function is uncertain...
  4. ncbi request reprint [Ambulatory blood pressure monitoring (CABPM): clinical characteristics of 31,530 patients]
    Cristina Sierra
    Unidad de Hipertension, Servicio de Medicina Interna, Hospital Clinic, Barcelona, Espana
    Med Clin (Barc) 129:1-5. 2007
    ..Ambulatory blood pressure monitoring (ABPM) is a useful diagnostic and therapeutic tool in hypertensive patients. This study reports the clinical characteristics of 31,530 patients included in the Spanish Registry of ABPM...
  5. ncbi request reprint Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre Madrid, Spain
    J Hypertens 25:1711-8. 2007
    ..Little data is available concerning the prognostic implications of renal function abnormalities, their evolution over time and the effects of nifedipine on such abnormalities in patients with stable angina pectoris...
  6. doi request reprint The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041, Madrid, Spain
    Adv Ther 30:1086-99. 2013
    ..The aim of the SEVITENSION study was to compare the central effects of PER/AML against renin-angiotensin system blockade with the angiotensin II receptor blocker olmesartan (OLM) plus AML...
  7. doi request reprint Can the effectiveness of hypertension management be improved?
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Autonoma University, 28041, Madrid, Spain
    Expert Rev Cardiovasc Ther 11:689-95. 2013
    ..This article discusses some of the challenges of hypertension management and reviews strategies and treatment advances that may pave the way to more effective BP control...
  8. doi request reprint Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition
    Julian Segura
    Hospital 12 de Octubre, Department of Nephrology, Hypertension Unit, Av Cordoba s n, 28041 Madrid, Spain
    Expert Opin Investig Drugs 22:915-25. 2013
    ..5 million deaths, about 12.8% of the total of all annual deaths. New drugs with different efficacy and effectiveness to control cardiovascular and renal disease are always welcomed...
  9. doi request reprint The Clinical Significance of Blood Pressure Lowering Treatment: First-Line Drug Choice is Important : The Pro Position
    Luis M Ruilope
    Hypertension Unit, Unidad de Hipertension, Hospital 12 de Octubre, Avda Cordoba s n, 28041, Madrid, Spain
    High Blood Press Cardiovasc Prev 15:113-5. 2008
    ..The way in which patients are treated can contribute to a better or worse protection beyond attaining blood pressure goals...
  10. doi request reprint Current status of renal denervation in resistant hypertension
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, and Department of Preventive Medicine and Public Health, Universidad Autonoma, Madrid, Spain
    J Am Soc Hypertens 6:414-6. 2012
    ..The technique is simple, safe, and available data indicates that it is effective. More data and longer follow-up of patients are required to promote wide acceptance of this new technique...
  11. doi request reprint Telmisartan 80 mg/hydrochlorothiazide 25 mg single-pill combination in the treatment of hypertension
    L M Ruilope
    Hospital 12 de Octubre, Nephrology, Carreter de Cordoba s N, Madrid, Spain
    Expert Opin Pharmacother 13:2417-25. 2012
    ..A single-pill combination (SPC) of telmisartan 80 mg with high-strength HCTZ 25 mg (T80/H25) is widely available...
  12. doi request reprint Current challenges in the clinical management of hypertension
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Avenida de Cordoba s n, Madrid, Spain
    Nat Rev Cardiol 9:267-75. 2012
    ..Further studies are required to define how antihypertensive therapy should be used in the earliest stages of hypertension and for the treatment of patients with a mild-to-moderate increase in global cardiovascular risk...
  13. ncbi request reprint Renin-angiotensin-aldosterone system blockade and renal protection: angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers?
    L M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Avenida Córdoba s n, 28041 Madrid, Spain
    Acta Diabetol 42:S33-41. 2005
    ..Long-term clinical studies now under way will help to establish the relative efficacies of the ARBs and ACE inhibitors and provide greater insight into the benefits of combination therapy...
  14. doi request reprint Left ventricular hypertrophy and clinical outcomes in hypertensive patients
    Luis M Ruilope
    Hospital 12 de Octubre, Avda de Cordoba s n, Madrid, Spain
    Am J Hypertens 21:500-8. 2008
    ..Guidelines, therefore, have recommended these drug classes for the treatment of hypertensive patients with LVH...
  15. ncbi request reprint New ADVANCEs in guidelines
    Luis M Ruilope
    , Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 26:S16-8. 2008
    ....
  16. doi request reprint The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy
    Luis M Ruilope
    Servicio de Nefrologia, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Clin Exp Hypertens 30:397-414. 2008
    ..ARBs decrease overall risk of CV and end-organ disease, CVD-related mortality, and cerebrovascular events in patients with hypertension...
  17. ncbi request reprint Public health value of fixed-dose combinations in hypertension
    Luis M Ruilope
    Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain
    Blood Press Suppl 1:5-14. 2008
    ..When FDCs are adopted for the treatment of hypertension, issues relating to copayment, formulary restrictions and therapeutic reference pricing must be addressed...
  18. ncbi request reprint Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    Clin Ther 27:578-87. 2005
    ..Recent antihypertensive treatment guidelines recommend greater use of combination therapies...
  19. ncbi request reprint Angiotensin receptor blockers: RAAS blockade and renoprotection
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Med Res Opin 24:1285-93. 2008
    ..The central role of the renin-angiotensin-aldosterone system (RAAS) in hypertension and renal disease has led to interest in the ability of RAAS-blocking agents to provide benefits beyond blood pressure control...
  20. ncbi request reprint Angiotensin receptor blockers: therapeutic targets and cardiovascular protection
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octobre, Madrid, Spain, and Division of Internal Medicine, Ospedali Civili, University of Brescia, Italy
    Blood Press 14:196-209. 2005
    ..Furthermore, evidence in favour of combining an ACE inhibitor and an ARB in certain circumstances is continuously growing...
  21. ncbi request reprint The kidney and cardiovascular risk--implications for management: a consensus statement from the European Society of Hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 16:72-9. 2007
    ....
  22. ncbi request reprint Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax)
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens Suppl 24:S9-12. 2006
    ..The fixed combination of perindopril/indapamide can greatly help clinicians in achieving the above goals, using Preterax in the early and BiPreterax in the late stages of nephropathy...
  23. ncbi request reprint Targeting hypertension with valsartan: Lessons learned from the Valsartan/HCTZ versus Amlodipine in stage II hypertensive patients (VASt) trial
    Luis M Ruilope
    Internal Medicine, Comlutense University, Madrid, Spain
    J Renin Angiotensin Aldosterone Syst 7:S8-11. 2006
    ..In addition, combination therapy resulted in a trend towards more favourable outcomes with respect to pro-thrombotic and proinflammatory markers than amlodipine alone...
  24. ncbi request reprint Renal AT 1 receptors and hypertension
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Nephrol Dial Transplant 22:2136-7. 2007
  25. pmc Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme
    Luis Miguel Ruilope
    Servicio de Nefrologia, Unidad de Hipertension Hospital, 12 de Octubre, Madrid, Spain
    Vasc Health Risk Manag 3:1-9. 2007
    ..Completion of ONTARGET is expected in 2008...
  26. ncbi request reprint New ADVANCEs in guidelines
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Avenida de Cordoba s n, 28041 Madrid, Spain
    J Hypertens Suppl 26:S16-8. 2008
    ..Guidelines also recognize the relevance of prediabetes, a situation characterized by the presence of the metabolic syndrome...
  27. doi request reprint ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Expert Opin Pharmacother 11:2619-23. 2010
    ....
  28. doi request reprint Efficacy of Sevikar® compared to the combination of perindopril plus amlodipine on central arterial blood pressure in patients with moderate-to-severe hypertension: Rationale and design of the SEVITENSION study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    Contemp Clin Trials 32:710-6. 2011
    ....
  29. doi request reprint Hypertension in 2010: Blood pressure and the kidney
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Avenida de Cordoba s n, 28041 Madrid, Spain
    Nat Rev Nephrol 7:73-4. 2011
    ..2010 saw the publication of a number of papers that provide new information on the relationship between blood pressure and the kidney. The data reinforce the need for future studies to jointly consider cardiovascular and renal outcomes...
  30. doi request reprint New clinical concepts after the ONTARGET trial
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Avda De Córdoba, s n 28041, Madrid, Spain
    Expert Rev Cardiovasc Ther 9:685-9. 2011
    ....
  31. doi request reprint Prevention of microalbuminuria in patients with type 2 diabetes: what do we know?
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Clin Hypertens (Greenwich) 12:422-30. 2010
    ....
  32. doi request reprint Telmisartan for the management of patients at high cardiovascular risk
    Luis M Ruilope
    Servicio de Nefrologia, Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Curr Med Res Opin 27:1673-82. 2011
    ..Angiotensin II receptor blockers (ARBs) offer a better tolerated alternative to angiotensin converting enzyme inhibitors, with greater long-term adherence. The ARB telmisartan recently received an indication for CV prevention...
  33. ncbi request reprint Public health value of fixed-dose combinations in hypertension
    Luis M Ruilope
    Hypertension Unit, 12 de Octubre Hospital, Madrid, Spain
    Blood Press Suppl 17:5-14. 2008
    ..When FDCs are adopted for the treatment of hypertension, issues relating to co-payment, formulary restrictions and therapeutic reference pricing must be addressed...
  34. doi request reprint Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study
    Luis Miguel Ruilope
    Division of Hypertension, Hospital 12 de Octubre, Madrid, Spain
    Lancet 375:1255-66. 2010
    ..We aimed to establish whether the dual actions of LCZ696 lead to further lowering of blood pressure, compared with the angiotensin-receptor blocker valsartan...
  35. ncbi request reprint 24-hour ambulatory blood-pressure effects of valsartan and hydrochlorothiazide combinations compared with amlodipine in hypertensive patients at increased cardiovascular risk: a VAST sub-study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain bNovartis AG, Basel, Switzerland
    Blood Press Monit 10:85-91. 2005
    ..There is a lack of data on the effects of angiotensin-receptor blocker and diuretic combinations on ambulatory blood pressure (ABP) in hypertensive patients with additional cardiovascular risk factors...
  36. doi request reprint Kidney protection: a key target in the management of patients with diabetes
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens Suppl 27:S15-8. 2009
    ..Evidence of renal protection is added to the reduction in total and cardiovascular mortality in the main ADVANCE trial...
  37. pmc Clinical efficacy and safety of olmesartan/hydrochlorothiazide combination therapy in patients with essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Vasc Health Risk Manag 4:1237-48. 2008
    ....
  38. doi request reprint Renal function and target organ damage in hypertension
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Eur Heart J 32:1599-604. 2011
    ..Renal protection will in turn obtain CV protection and the treatment to be used is similar to that employed to prevent or to treat established CV disease...
  39. ncbi request reprint Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Clin Ther 25:3044-64. 2003
    ..Preventing or delaying the progression of renal disease from microalbuminuria to nephropathy, and ultimately, to ESRD is thus a crucial goal of DM management...
  40. ncbi request reprint Spotlight on renin: cardiovascular outcomes in chronic kidney disease and suppression of the renin-angiotensin system
    Jose A Garcia-Donaire
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Renin Angiotensin Aldosterone Syst 7:56-8. 2006
  41. ncbi request reprint Angiotensin receptor blockade in diabetic renal disease--focus on candesartan
    Jose A Garcia Donaire
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Diabetes Res Clin Pract 76:S22-30. 2007
    ..When given in addition to an ACE inhibitor (dual blockade), reductions in UAE of 25-35% relative to ACE inhibitor monotherapy have been found...
  42. ncbi request reprint Calcium channel blockers and renal protection: insights from the latest clinical trials
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Am Soc Nephrol 16:S64-6. 2005
    ....
  43. ncbi request reprint Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 16:422-6. 2007
    ....
  44. ncbi request reprint How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Curr Hypertens Rep 5:426-9. 2003
    ..The aim of this paper is to briefly review the evidence in favor of uptitration of either class of inhibitors of the renin-angiotensin system as compared with the combination of the two for the control of either BP or proteinuria...
  45. ncbi request reprint N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients
    Vivencio Barrios
    Department of Cardiology, Hospital Ramon y Cajal, Madrid, Spain
    Blood Press 11:235-9. 2002
    ..This effect may be mediated by an NO-dependent mechanism, probably through the protective effect of NAC on NO oxidation...
  46. ncbi request reprint Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses
    Juliá Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, 28041, Spain
    J Renin Angiotensin Aldosterone Syst 4:43-7. 2003
    ..Both ACE-I and ARB were titrated as monotherapy up to the maximal recommended dose...
  47. ncbi request reprint Clinical trials in nephrology: success or failure
    Jose A Garcia-Donaire
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 16:59-63. 2007
    ..Suppression of the rennin-angiotensin-aldosterone system should also be considered in any patient with chronic kidney disease, in particular if albuminuria is present...
  48. ncbi request reprint Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PResión Arterial en DIabéticos tipo Dos) study
    Luis M Ruilope
    Hypertension Unit, Hospital 12 du Octubre, Madrid, Spain
    J Hypertens 22:217-22. 2004
    ....
  49. ncbi request reprint Obesity, essential hypertension and renin-angiotensin system
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Public Health Nutr 10:1151-5. 2007
    ..This review discusses the role of RAS in the relationship between obesity, essential hypertension and insulin resistance...
  50. doi request reprint Hyperkalemia risk and treatment of heart failure
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Heart Fail Clin 4:455-64. 2008
    ..This article briefly reviews the participation of the kidney in heart failure and the renal consequences of the treatment, with special emphasis on the risk for hyperkalemia and its management in daily clinical practice...
  51. doi request reprint Should diuretics always be included as initial antihypertensive management in early-stage CKD?
    Julian Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid 28041, Spain
    Curr Opin Nephrol Hypertens 18:392-6. 2009
    ..This review focuses on the need for combined antihypertensive therapy drugs in patients with chronic kidney disease and the relevance of diuretics...
  52. ncbi request reprint Effects of telmisartan 80 mg and valsartan 160 mg on ambulatory blood pressure in patients with essential hypertension
    Carlos Calvo
    Hypertension and Vascular Risk Unit, Hospital Clinico Universitario, Santiago de Compostela, Madrid, Spain
    J Hypertens 22:837-46. 2004
    ..This trial investigated and compared the antihypertensive efficacy of telmisartan and valsartan, two angiotensin II receptor blockers, used in monotherapy at their maximum recommended dose in hypertensive patients...
  53. ncbi request reprint Long-term protection in at-risk hypertensive patients--a role for nifedipine GITS?
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Blood Press 11:106-9. 2002
    ..The results from INSIGHT support incorporating nifedipine GITS in the management of high-risk hypertensive patients to prevent atherosclerosis-related illness and death...
  54. ncbi request reprint Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Fundam Clin Pharmacol 19:429-37. 2005
    ..The high prevalence of chronic kidney disease in the general and in the hypertensive populations implies the need for an integrative therapeutic approach to fully protect renal and cardiovascular systems simultaneously...
  55. ncbi request reprint Valsartan improves fibrinolytic balance in atherosclerotic rabbits
    M Pilar Oubina
    Departmento de Fisiologia, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    J Hypertens 20:303-10. 2002
    ..To examine the long-term effects of the angiotensin type I (AT1) receptor antagonist, valsartan, on fibrinolytic balance, coagulation parameters, endothelial function and structural alterations in atherosclerotic rabbits...
  56. ncbi request reprint Lessons from trials in hypertensive type 2 diabetic patients
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
    Curr Hypertens Rep 5:322-8. 2003
    ..However, by attaining normal blood pressure levels (< 130/80 mm Hg), better preservation of glomerular filtration rate does not seem to be insured...
  57. ncbi request reprint Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients
    Julian Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    J Am Soc Nephrol 15:1616-22. 2004
    ..In essential hypertensive patients with normal renal function at baseline, the development of CKD during the follow-up is strongly and independently related with poor cardiovascular prognosis...
  58. ncbi request reprint Development of chronic kidney disease in essential hypertension during long-term therapy
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 13:495-500. 2004
    ..This review examines the relevance of the development of chronic kidney disease in long-term hypertensive patients on the cardiovascular prognosis...
  59. pmc Trandolapril/verapamil combination in hypertensive diabetic patients
    Jose A Garcia Donaire
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Vasc Health Risk Manag 3:77-82. 2007
    ..This combination can be considered as an effective therapy for the diabetic hypertensive population...
  60. ncbi request reprint The kidney as a sensor of cardiovascular risk in essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, Madrid, Spain
    J Am Soc Nephrol 13:S165-8. 2002
    ..Prevention and protection of renal and cardiovascular damage in these patients will be one of the most relevant tasks in the future...
  61. doi request reprint Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients
    Alejandro de la Sierra
    Hypertension Unit, Department of Internal Medicine, Hospital Clinic, University of Barcelona, Villarroel 170, E 08036 Barcelona, Spain
    Hypertension 53:466-72. 2009
    ..A clinical pattern of high cardiovascular risk is associated with nondipping, suggesting that the blunted nocturnal BP dip may be merely a marker of high cardiovascular risk...
  62. ncbi request reprint Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension
    Carlos Campo
    Unidad de Hipertension, Departamento de Bioquimica, Hospital Universitario 12 de Octubre, Madrid, Spain
    Blood Press 12:277-83. 2003
    ..Hyperuricemia has been shown to be associated with an increased risk of cardiovascular disease in hypertensive patients in some but not in all epidemiological studies in which this relationship has been investigated...
  63. ncbi request reprint Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension
    Carlos Campo
    Hypertension Unit, Hospital Universitario 12 de Octubre, Madrid ES 28041, Spain
    Blood Press Suppl 2:16-21. 2003
    ..Therefore, in patients not controlled with monotherapy, doxazosin GITS can be considered an alternative to the addition of thiazide diuretics...
  64. doi request reprint How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?
    Finn Gustafsson
    Department of Cardiology, University of Copenhagen, Denmark bHypertension Unit, Hospital 12 de Octubre, Rigshospitalet, Madrid, Spain
    J Hypertens 28:1595-8. 2010
    ..In this review possible strategies are outlined and important areas for research are identified. It is suggested that trials are designed specifically to address prognosis and treatment in this growing population...
  65. ncbi request reprint Proteinuria: an underappreciated risk factor in cardiovascular disease
    Julian Segura
    Unidad de Hipertension Arterial, Hospital 12 de Octubre, Avenida Córdoba s n, 28041 Madrid, Spain
    Curr Cardiol Rep 4:458-62. 2002
    ..All these parameters should routinely be evaluated in clinical practice, and in the future must be considered in any stratification of cardiovascular risk in hypertensive patients...
  66. ncbi request reprint Renal protection by antihypertensive therapy
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, 28041 Madrid, Spain
    Curr Hypertens Rep 4:324-8. 2002
    ..The control of other associated risk factors is also required, in particular smoking and lipids...
  67. doi request reprint Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 26:357-67. 2008
    ..This analysis assessed the impact of rimonabant on blood pressure in the pooled population from four large trials with similar design - the Rimonabant-In-Obesity (RIO) programme...
  68. ncbi request reprint Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Clin Ther 27:1658-68. 2005
    ..In addition, the risk associated with hypertension is graded, continuous, and independent of other risk factors, and this is not reflected in classic models of risk assessment...
  69. ncbi request reprint Do we need to target 'prediabetic' hypertensive patients?
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 23:2119-25. 2005
    ....
  70. ncbi request reprint Effectiveness of blood pressure control outside the medical setting
    Jose R Banegas
    Department of Preventive Medicine and Public Health, Autonomous University of Madrid, Madrid, Spain
    Hypertension 49:62-8. 2007
    ..However, the burden of underestimation and overestimation of BP control at the office is still remarkable. Physicians should be aware that the likelihood of misestimating BP control is higher in some hypertensive subjects...
  71. ncbi request reprint Glucose metabolism in patients with essential hypertension
    Juan Garcia-Puig
    Division of Internal Medicine at Hospital Universitario La Paz, Madrid, Spain
    Am J Med 119:318-26. 2006
    ..Arterial hypertension is an insulin-resistant condition that has been associated with an increased incidence of diabetes. We assessed the prevalence of glucose abnormalities in a population of patients with essential hypertension...
  72. ncbi request reprint Recent developments in the treatment of type 2 diabetes mellitus
    Luis M Ruilope
    Hospital 12 de Octubre, Servicio de Nefrologia, Madrid, Spain
    Cardiovasc Drugs Ther 17:151-8. 2003
    ..Agents that interfere with the renin-angiotensin system, particularly angiotensin-receptor blockers, may have particular benefits on end-organs in diabetic patients...
  73. ncbi request reprint Renal participation in cardiovascular risk in essential hypertension
    Luis M Ruilope
    Unidad de Hipertension, Hospital 12 de Octubre, Madrid, Spain
    Expert Rev Cardiovasc Ther 1:309-15. 2003
    ....
  74. doi request reprint Gender differences in office and ambulatory control of hypertension
    Jose R Banegas
    Department of Preventive Medicine and Public Health, Universidad Autonoma de Madrid, CIBER en Epidemiología y Salud Pública, Madrid, Spain
    Am J Med 121:1078-84. 2008
    ..Gender differences in hypertension control have not been explored fully...
  75. ncbi request reprint How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?
    Julian Segura
    Unidad de Hipertension, Servicio de Nefrologia, Hospital 12 de Octubre, 28041 Madrid
    J Clin Hypertens (Greenwich) 4:332-6. 2002
    ..This fact reinforces the need to pay attention to any of the manifestations of renal damage observed in the usual clinical assessment of any hypertensive patient...
  76. ncbi request reprint Prediabetes and cardiovascular risk in hypertensive patients
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Av Cordoba s n, 28041 Madrid, Spain
    Curr Hypertens Rep 8:97-100. 2006
  77. ncbi request reprint On the importance of estimating renal function for cardiovascular risk assessment
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    J Hypertens 22:1635-9. 2004
    ..This evidence is of great relevance because it constitutes the first evidence showing that regression of an intermediate end-point, microalbuminuria, ensures a better cardiovascular prognosis...
  78. ncbi request reprint Antihypertensive efficacy and tolerability of lercanidipine in daily clinical practice. The ELYPSE Study. Eficacia de Lercanidipino y su Perfil de Seguridad
    Vivencio Barrios
    Servicio de Cardiologia, Hospital Ramon y Cajal, Madrid, Spain
    Blood Press 11:95-100. 2002
    ..With the aim to determine the efficacy and tolerability of this drug in usual clinical practice we performed the ELYPSE trial...
  79. ncbi request reprint [PREVENCAT study: control of cardiovascular risk in primary care]
    Luis A Alvarez-Sala
    Departamento de Medicina, Hospital General Universitario Gregorio Maranon, Facultad de Medicina, Universidad Complutense, Madrid, Spain
    Med Clin (Barc) 124:406-10. 2005
    ....
  80. ncbi request reprint Eprosartan for the treatment of hypertension
    Luis Ruilope
    Hypertension Unit, Hospital 12 de Octubre, 28041 Madrid, Spain
    Expert Opin Pharmacother 4:107-14. 2003
    ..Eprosartan is safe, effective and well-tolerated in long-term treatment, either as a monotherapy or in combination with other antihypertensive drugs such as hydrochlorothiazide...
  81. ncbi request reprint ACE inhibition and cardiovascular mortality and morbidity in essential hypertension: the end of the search or a need for further investigations?
    Luis M Ruilope
    Hypertension Unit, Hospital 12 de Octubre, Complutense University, Madrid, Spain
    Am J Hypertens 15:367-71. 2002
    ....
  82. ncbi request reprint The pathophysiology of hyperuricemia in essential hypertension: a pilot study
    Juan G Puig
    Division of Internal Medicine, Hospital La Paz, Madrid, Spain
    Nucleosides Nucleotides Nucleic Acids 23:1197-9. 2004
    ..Simultaneously, urinary sodium to creatinine ratio decreased by a mean of 54%. These results suggest that insulin may mediate uric acid underexcretion due to its tubular sodium retaining effect in essential hypertensive patients...
  83. ncbi request reprint Antihypertensive therapy in patients with metabolic syndrome
    Julian Segura
    Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Curr Opin Nephrol Hypertens 15:493-7. 2006
    ..Metabolic syndrome can be considered as a prediabetic state very frequently associated with arterial hypertension, requiring pharmacological therapy...
  84. ncbi request reprint AT1 blockers and uric acid metabolism: are there relevant differences?
    Juan G Puig
    Divisions of Internal Medicine, La Paz University Hospital, Madrid, Spain
    J Hypertens Suppl 20:S29-31. 2002
    ..The development of several AT1 receptor blockers raises the question whether these antihypertensive drugs influence uric acid metabolism...
  85. ncbi request reprint [New targets in patients with cardiometabolic risk]
    Luis Miguel Ruilope
    Med Clin (Barc) 129:576-7. 2007
  86. ncbi request reprint Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry
    Raquel Hernández-del Rey
    Hypertension and Vascular Risk Unit, Department of Internal Medicine, Hospital General de L Hospitalet, University of Barcelona, Spain
    J Hypertens 25:2406-12. 2007
    ..To assess the reproducibility of the circadian blood pressure (BP) pattern over a 48-h period by comparing the first 24 h of ambulatory blood pressure monitoring (ABPM) with the following 24 h and with the mean over 48 h...
  87. doi request reprint Clinical characteristics of isolated clinic hypertension
    Ernest Vinyoles
    La Mina Primary Care Center, Catalan Health Institute, Barcelona, Spain
    J Hypertens 26:438-45. 2008
    ..To analyze the clinical characteristics of patients with isolated clinic hypertension (ICH) compared with other hypertensive patients, and to evaluate the capacity of physicians to predict a diagnosis of ICH...
  88. ncbi request reprint An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy
    José Antonio García-Donaire
    Hypertension Unit, Hospital 12 de Octubre, Av Córdoba s n28041 Madrid, Spain
    Expert Opin Pharmacother 6:1587-96. 2005
    ....
  89. pmc Prospects for renovascular protection by more aggressive renin-angiotensin system control
    Luis Miguel Ruilope
    Nephrology Service, Hypertension Unit, Hospital 12 de Octubre, Madrid, Spain
    Medscape J Med 10:S5. 2008
    ..The ultimate proof of benefit will come from the ONTARGET trial, which will evaluate the cardiovascular and renal protective effects of the combination of telmisartan and ramipril...
  90. ncbi request reprint Prevalence of renal insufficiency in individuals with hypertension and obesity/overweight: the FATH study
    Pablo Gomez
    Nephrology Department, Hospital del SAS, Jerez de la Frontera, Madrid, Spain 11407
    J Am Soc Nephrol 17:S194-200. 2006
    ..40; 95% CI 0.84 to 2.33). It was concluded that patients who have hypertension and visceral obesity and attend primary care present a higher prevalence of metabolic syndrome and RI...
  91. ncbi request reprint Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome?
    Julian Segura
    Hypertension Unit, Nephrology Department, Hospital 12 de Octubre, Madrid, Spain
    J Clin Hypertens (Greenwich) 9:595-600. 2007
    ..Global CV risk, however, remained higher in MS patients, as suggested by a 3-fold higher incidence of new-onset diabetes (absolute increase of 5.6%) and a 2-fold increase in microalbuminuria...
  92. ncbi request reprint Efficacy of eplerenone versus enalapril as monotherapy in systemic hypertension
    Gordon H Williams
    Brigham and Women s Hospital, Boston, Massachusetts, USA
    Am J Cardiol 93:990-6. 2004
    ..Eplerenone was as effective as enalapril as monotherapy in patients with stage 1 or 2 hypertension, was more effective in reducing albuminuria, and was well tolerated for 12 months...
  93. ncbi request reprint Spotlight: Luis Miguel Ruilope, MD
    Emma Baines
    Circulation 115:f43-4. 2007
  94. ncbi request reprint [Stratification and degree of control of cardiovascular risk factors in hypertensive Spanish population. Results of the DICOPRESS study]
    Montserrat Martin-Baranera
    Unidad de Epidemiologia, Consorci Sanitari Integral, Barcelona, Espana
    Med Clin (Barc) 129:247-51. 2007
    ....
  95. ncbi request reprint [Renal function protection in type 2 diabetic patients]
    Luis Miguel Ruilope
    Med Clin (Barc) 118:297-8. 2002
  96. ncbi request reprint [Selective inhibitors of cyclooxigenase-2 (Coxibs) and cardiovascular morbidity]
    Luis Miguel Ruilope
    Med Clin (Barc) 118:219-21. 2002
  97. ncbi request reprint Management of cardiovascular risk factors in patients with metabolic syndrome
    Alejandro de la Sierra
    Hypertension Unit, Department of Internal Medicine, Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
    Cardiovasc Hematol Agents Med Chem 5:209-14. 2007
    ..There is an urgent need for consensus in the treatment of subjects with metabolic syndrome in order to prevent very high future rates of type 2 diabetes and cardiovascular disease...
  98. ncbi request reprint [Effectiveness and safety of calcium antagonists in hypertensive patients]
    Luis Miguel Ruilope
    Med Clin (Barc) 125:412-4. 2005